CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
The long battle over BRCA1 and BRCA2 patent infringement finally comes to an end.
Roche are planning on spending $1 billion to take majority control of Foundation Medicine.
Illumina step up their healthcare plans with Lockheed Martin collaboration.
23andMe & Genentech partner to find new therapeutic targets for Parkinson’s
Claritas Genomics have selected NextCODE Health to help improve their genomic capabilities…..